Fundraising Fox

Syndax Pharmaceuticals

NASDAQ: SNDX

Waltham, US · Incorporated in Delaware · 3 known investors

Biotech

Founders & leadership

DP
Dennis PodlesakNamed on SEC filing
IR
Ivor RoystonNamed on SEC filing
JP
John PalliesNamed on SEC filing
LE
Luke Evnin, Ph.D.Named on SEC filing
GW
George W Sledge, Jr. M.D.Named on SEC filing
FE
Fabrice Egros, Ph.D.Named on SEC filing
AM
Arlene MorrisNamed on SEC filing
RP
Richard P SheaNamed on SEC filing
KK
Kim Kamdar, Ph.DNamed on SEC filing

Investors · 3

Foresite CapitalLarkspur
Sofinnova VenturesMenlo Park · $100K – $15M
venBio PartnersSan Francisco

Reported raises · per SEC filings

Form D private placements

$93.2M disclosed across 5 rounds · 2014–2015

▶$61.3MraisedAug 2015 · 19 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Dennis PodlesakDirector
  • Fabrice Egros, Ph.D.Director
  • Michael MetzgerExecutive Officer
  • Kim Kamdar, Ph.DDirector
  • Luke Evnin, Ph.D.Director
  • Ivor Royston, M.D.Director
  • George W Sledge, Jr., M.D.Director
  • John PalliesExecutive Officer
  • Richard P SheaDirector
  • Henry ChenDirector
  • Briggs Morrison, M.D.Executive Officer, Director
Offering amount
$61.3M
Amount sold
$61.3M
First sale
Aug 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$24MraisedJun 2015 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • George W Sledge, Jr. M.D.Director
  • Richard P SheaDirector
  • Ivor RoystonDirector
  • Fabrice Egros, Ph.D.Director
  • Luke Evnin, Ph.D.Director
  • Henry ChenDirector
  • Michael MetzgerExecutive Officer
  • John PalliesExecutive Officer
  • Dennis PodlesakDirector
  • Kim Kamdar, Ph.DDirector
Offering amount
$45.2M
Amount sold
$24M
First sale
Jun 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.9MraisedSep 2014 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Fabrice Egros, Ph.D.Director
  • George W Sledge, Jr. M.D.Director
  • Arlene MorrisExecutive Officer, Director
  • John PalliesExecutive Officer
  • Dennis PodlesakDirector
  • Kim Kamdar, Ph.DDirector
  • Ivor RoystonDirector
  • Luke Evnin, Ph.D.Director
  • Richard P SheaDirector
Offering amount
$5M
Amount sold
$4.9M
First sale
Sep 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.7MraisedFeb 2014 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Dennis PodlesakDirector
  • Ivor RoystonDirector
  • John PalliesExecutive Officer
  • Luke Evnin, Ph.D.Director
  • George W Sledge, Jr. M.D.Director
  • Fabrice Egros, Ph.D.Director
  • Arlene MorrisExecutive Officer, Director
  • Richard P SheaDirector
  • Kim Kamdar, Ph.DDirector
Offering amount
$1.7M
Amount sold
$1.7M
First sale
Feb 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedFeb 2014 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Dennis PodlesakDirector
  • Luke Evnin, Ph.D.Director
  • Ivor RoystonDirector
  • Arlene MorrisExecutive Officer, Director
  • Kim Kamdar, Ph.DDirector
  • Fabrice Egros, Ph.D.Director
  • John PalliesExecutive Officer
  • Richard P SheaDirector
Offering amount
$1.3M
Amount sold
$1.3M
First sale
Jan 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Syndax (SNDX) Q2 2026 Earnings Call Transcript - AOLaol.com · Aug 2026State Street reports 6.4% stake in Syndax Pharmaceuticals | SNDX SEC Filing - Form SCHEDULE 13Gstocktitan.net · Aug 2026Syndax Pharmaceuticals Q2 2026 revenue rises, loss narrows | SNDX Quarterly Report (10-Q)stocktitan.net · Aug 2026Syndax Pharmaceuticals, Inc. (SNDX) Investor Outlook: A Promising 83.88% Upside Potentialdirectorstalkinterviews.com · Jul 2026

Frequently asked questions

Who are Syndax Pharmaceuticals's investors?
Syndax Pharmaceuticals's investors include Foresite Capital, Sofinnova Ventures, venBio Partners.
How much funding has Syndax Pharmaceuticals raised?
Syndax Pharmaceuticals has disclosed $93.2M raised across 5 rounds.
Where is Syndax Pharmaceuticals headquartered?
Syndax Pharmaceuticals is headquartered in Waltham, US.